Recce Pharmaceuticals (ASX:RCE) has received a boost to the development of its topical gel for the treatment of diabetic foot infections, as 20 more patients with the condition are added to its Phase II clinical trial of the product, R327G.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The inclusion of these participants – enabled through Human Ethics Approval – comes on the back of positive results from this open-label trial, which showed a successful clinical response among 86% of patients after seven days of treatment; the same for more than 90% of patients after 14 days.
Crucially, the former is the main endpoint used by the U.S. FDA.
Data from the Phase II trial has led investigators to surmise R327G a safe and efficacious treatment for DFI, particularly given that, through the use of a gel, patients can avoid having to use oral or IV antibiotics for the condition.
“This approval allows us to build upon the strong clinical results of R327G and continue demonstrating its potential as a differentiated treatment for DFIs,” Recce CEO James Grahama said today.
Mr Graham continued: “We are pleased to continue to provide access to R327G to diabetic patients in need, and to further build out our data portfolio alongside our Phase Three programs in both Australia and Indonesia.”
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)